Abstracts tagged "Osteoarthritis"

Abstract Number: 1323 • 2019 ACR/ARP Annual Meeting
Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma
Lilian SOLE¹, Arthur Beck ¹, Thomas Barnetche ² and Pascale Vergne-Salle ³, ¹CHU de Limoges, LIMOGES, France, ²CHU, Toulouse, France, ³CHU limoges, Limoges, France
Background/Purpose: While there is growing evidences for the efficacy of platelet-rich plasma (PRP), there is still no standardized composition. There are 3 major types of…
Abstract Number: 1976 • 2019 ACR/ARP Annual Meeting
Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5
Mahamudul Haque¹, Madeline McDougal ¹, Anil Singh ¹ and Salahuddin Ahmed ², ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, SPOKANE, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Osteoarthritis (OA) is a chronic degenerative joint disease caused by synovial inflammation and cartilage degradation primarily driven by interleukin-1beta (IL-1β). Studies suggest that TNF-stimulated…
Abstract Number: 2176 • 2019 ACR/ARP Annual Meeting
A Novel Composite Score Reflecting Disease Activity Predicts Future Knee Replacements: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Matthew Harkey ², Lori Lyn Price ³, Grace Lo ⁴, Jincheng Pang ⁵, Ming Zhang ⁶ and Timothy McAlindon ¹, ¹Tufts Medical Center, Boston, MA, ²Tufts Medical Center, University of Massachusetts Medical School, Boston, MA, ³Tufts Medical Center, Tufts University, Boston, MA, ⁴Center of Excellence Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, TX, ⁵Pfizer, Inc., Cambridge, MA, ⁶Tufts Medical Center, Wentworth Institute of Technology, Boston, MA
Background/Purpose: While knee osteoarthritis (KOA) leads to cumulative damage to a diarthrodial joint there are also more dynamic processes that fluctuate throughout the disease process…
Abstract Number: 2199 • 2019 ACR/ARP Annual Meeting
Is There an Association of Serum LDL, HDL and Total Cholesterol with the Development of Knee Osteoarthritis?
Jessica Barlow¹, Xianbang Sun ², Michael Nevitt ³, James Torner ⁴, Beth Lewis ⁵, Nirupa Matthan ⁶, Alice Lichtenstein ⁶ and David Felson ⁷, ¹Boston University School of Medicine, Department of Rheumatology, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³University of California at San Francisco, San Francisco, CA, ⁴University of Iowa at Iowa City, Iowa City, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Tufts University, Boston, MA, ⁷Boston University School of Medicine, Department of Rheumatology, Boston
Background/Purpose: Recent data have suggested an association between elevated serum cholesterol levels, particularly low density lipoprotein (LDL), and the development of osteoarthritis (OA). Within the…
Abstract Number: 2891 • 2019 ACR/ARP Annual Meeting
Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs
James Sullivan¹, Jeffrey Katz ² and Elena Losina ³, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital/Harvard Medical School, Boston, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Knee OA is a disabling condition affecting over 14 million adults in the US. NSAIDs provide only short-term pain relief, creating the need for…
Abstract Number: 269 • 2019 ACR/ARP Annual Meeting
Attitudes and Beliefs About Opioid Medications: Determining Treatment Use in Osteoarthritis
Ernest Vina¹, Jazmin Dagnino ¹ and C. Kent Kwoh ¹, ¹University of Arizona, Tucson, AZ
Background/Purpose: Considering the growing opioid epidemic in the US, it is imperative to have a good understanding of what patient characteristics predict the use of…
Abstract Number: 1302 • 2019 ACR/ARP Annual Meeting
Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Marc C. Hochberg¹, John Carrino ², Thomas Schnitzer ³, Ali Guermazi ⁴, Eric Vignon ⁵, David Walsh ⁶, Alexander White ⁷, Satoru Nakajo ⁸, Robert Fountaine ⁹, Anne Hickman ⁹, Glenn Pixton ¹⁰, Lars Viktrup ¹¹, Mark T. Brown ⁹, Christine R. West ⁹ and Kenneth M. Verburg ⁹, ¹University of Maryland School of Medicine, Baltimore, MD, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Boston Medical Center, Boston, ⁵Université Claude Bernard Lyon 1, Lyon, France, ⁶Sherwood Forest Hospitals NHS Foundation Trust, Nottingham, United Kingdom, ⁷Progressive Medical Research, Port Orange, FL, ⁸Nakajo Orthopaedic Clinic, Miyagi, Japan, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Morrisville, NC, ¹¹Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab is a monoclonal antibody that inhibits nerve growth factor and is under investigation for chronic pain treatment. Tanezumab administered intravenously was effective and…
Abstract Number: 1324 • 2019 ACR/ARP Annual Meeting
Visceral Fat Deposition Associated with Pain in Osteoarthritis
Shanshan Li ¹, Nancy Desai², Tuhina Neogi ³, Ann Schwartz ⁴, Lavalley Michael ¹, Na Wang ³, Xianbang Sun ¹, Michael Nevitt ⁵, Beth Lewis ⁶, Ali Guermazi ², Frank Roemer ⁷, Neil Segal ⁸ and David Felson ⁹, ¹Boston University, Boston, ²Boston Medical Center, Boston, ³Boston University School of Medicine, Boston, MA, ⁴University of California San Francisco, San Francisco, ⁵University of California at San Francisco, San Francisco, CA, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸University of Kansas Medical Center, Kansas City, KS, ⁹Boston University School of Medicine, Department of Rheumatology, Boston
Background/Purpose: Animal model studies have demonstrated the significant role of inflammation in the pathogenesis of osteoarthritis (OA) and of pain. Visceral fat, rather than subcutaneous…
Abstract Number: 1977 • 2019 ACR/ARP Annual Meeting
The Synthesis of Hydrogen Sulfide Is Impaired in Osteoarthritic Chondrocytes from Diabetic Patients and in Vitro in Cells Under High Glucose Environment
Carlos Vaamonde-García¹, Tamara Hermida-Gómez ², Francisco J. Blanco ³, Elena F Burguera ³ and Rosa Meijide-Faílde ¹, ¹Tissue Engineering and Regenerative Medicine Group. University of A Coruña, A Coruña, Spain, ²Unidad de Bioingeniería Tisular y Terapia Celular (GBTTC-CHUAC). Grupo de Investigación en Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Centro de Investigaciones Científicas Avanzadas (CICA), A Coruña, Spain, ³Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: A growing number of findings indicates that type 2 diabetes is an independent risk factor of osteoarthritis (OA). However, the mechanisms underlying the connection…
Abstract Number: 2177 • 2019 ACR/ARP Annual Meeting
Sarcopenia and the Likelihood of Incident Knee Osteoarthritis and Knee Pain Among Older Adults in the Health ABC Study
James Andrews¹, Laura Gold ¹, Michael Nevitt ², Patrick Heagerty ¹ and Peggy Cawthon ³, ¹University of Washington, Seattle, ²University of California at San Francisco, San Francisco, CA, ³University of California San Francisco, San Francisco
Background/Purpose: Osteoarthritis (OA) disproportionately affects older adults. Sarcopenia, or reduced muscle mass and strength, is strongly associated with reduced physical function and poor clinical outcomes…
Abstract Number: 2200 • 2019 ACR/ARP Annual Meeting
Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis
Sheue-Fang Shih¹, Carl Brown ¹, Tien-Tzu Tai ¹ and Wing Chuang ¹, ¹Taiwan Liposome Company, Ltd., Taipei, Taiwan (Republic of China)
Background/Purpose: The most commonly used intra-articular (IA) corticosteroid for osteoarthritis (OA) is triamcinolone acetonide (TA), but its potential chondrotoxicity restricts injection frequency to 3-4 injections…
Abstract Number: 2926 • 2019 ACR/ARP Annual Meeting
Knee Injury and Transitions Among States of Knee Osteoarthritis in the Johnston County Osteoarthritis Project: A Multi-State Time-To-Event Modeling Approach
Yvonne Golightly¹, Carolina Alvarez ², Liubov Arbeeva ², Rebecca Cleveland ³, Todd Schwartz ⁴, Louise Murphy ⁵, Jordan Renner ⁶, Leigh Callahan ³, Joanne Jordan ² and Amanda Nelson ⁷, ¹University of North Carolina at Chapel Hill Department of Epidemiology and Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ³Thurston Arthritis Research Center, Chapel Hill, NC, ⁴University of North Carolina at Chapel Hill Department of Biostatistics, Chapel Hill, NC, ⁵Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ⁶University of North Carolina at Chapel Hill Department of Radiology, Chapel Hill, NC, ⁷University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Musculoskeletal injury is a known risk factor for osteoarthritis (OA). Cumulative effects of comorbid conditions on the association of injury and OA have not…
Abstract Number: 281 • 2019 ACR/ARP Annual Meeting
Frequency of Ultrasound Features of Knee Osteoarthritis and Their Association with Radiographic Features and Symptoms in a Community-Based Cohort
Nadiya Yerich¹, Carolina Alvarez ², Todd Schwartz ³, Sue Savage-Guin ², Catherine Bakewell ⁴, Minna Kohler ⁵, Janice Lin ⁶, Jonathan Samuels ⁷ and Amanda Nelson ², ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ³University of North Carolina at Chapel Hill Department of Biostatistics, Chapel Hill, NC, ⁴Intermountain Medical Center, Salt Lake City, UT, ⁵MGH, Boston, ⁶Stanford University, Palo Alto, CA, ⁷NYU Langone Medical Center, New Yort, NY
Background/Purpose: To evaluate the frequency and associations of osteoarthritis (KOA) features on knee ultrasound (KUS) in a community-based cohort study with radiographic and symptomatic data…
Abstract Number: 1303 • 2019 ACR/ARP Annual Meeting
Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA
Dawn McGuire¹, Michael Bowes ², Alan Brett ², Neil Segal ³, Meghan Miller ⁴, David Rosen ⁴ and Yoshinari Kumagai ⁴, ¹OrthoTrophix, Orinda, CA, ²Imorphics, Manchester, England, United Kingdom, ³University of Kansas Medical Center, Kansas City, KS, ⁴OrthoTrophix, Oakland, CA
Background/Purpose: Pathological bone shape changes in the femur precede cartilage changes in knee OA and predict disease onset and progression to joint failure (Neogi 2013;…
Abstract Number: 1325 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA
Agnès Lalande ¹, Nadya Kuzniatsova-Mouchette ², Florian Chassereau ¹, Julia Geronimi ¹, Staffan Larsson ³, Andre Struglics ³, Stefan Lohmander ³ and Maria Pueyo¹, ¹Institut de Recherches Internationales Servier, Suresnes, France, Suresnes, France, ²Institut de Recherches Internationales Servier, Suresnes, France, Suresnes, ³Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden, Lund, Sweden
Background/Purpose: The disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5) is a key enzyme in OA (Verma P, et al. J Cell Biochem 2011;112:3507-14). In preclinical models…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].